

<b>Notice of References Cited</b>	Application/Control No. 09/724,575	Applicant(s)/Patent Under Reexamination SCHENK, DALE B.	
	Examiner Christopher Nichols, Ph.D.	Art Unit 1647	Page 1 of 5

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 99/06545	02-1999	WIPO	MAX PLANK INSTITUTE	C12N 15/12
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Jen et al. (1997) Preparation and Purification of antisera against different regions or isoforms of beta-amyloid precursor protein. Brain Research Protocols 2:23-30.
	V	Jobling et al, Mol. Microbiol., 1991, 5(7):1755-67.
	W	Skolnick and Fetrow (2000) From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era. Trends in Biotech 18(1); 34-39.
	X	Chen et al. (1998) Neurodegenerative Alzheimer-like pathology in PDAPP 717V--F transgenic mice. Progress in Br. Res. 117:327-34.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No. 09/724,575	Applicant(s)/Patent Under Reexamination SCHENK, DALE B.	
	Examiner Christopher Nichols, Ph.D.	Art Unit 1647	Page 2 of 5

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Tennent, Lovat, and Pepys (1995) Serum Amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. PNAS 92: 4299-4303.
	V	Stein and Johnson (2002) Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and the Activation of Cell Survival Pathways. J Neuroscience 22(17): 7380-7388.
	W	Tanaka et al. (1998) NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats. European Journal of Pharmacology 352: 135-142.
	X	Esiri (2001) Is an Effective Immune Intervention for Alzheimer's Disease in Prospect? Trends in Pharm Science 22(1): 2-3.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**Notice of References Cited**

Application/Control No.

09/724,575

Applicant(s)/Patent Under  
Reexamination  
SCHENK, DALE B.

Examiner

Christopher Nichols, Ph.D.

Art Unit

1647

Page 3 of 5

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Younkin (2001) Amyloid beta Vaccination: Reduced Plaques and Improved Cognition. Nature Medicine 7(1):18-19.
	V	St-George-Hyslop and Westaway (1999) Antibody Clears Senile Plaques. Nature 400:116-117.
	W	ELAN "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792." Press Release (28.Jan.2002)
	X	ELAN "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration" Press Release (1.Mar.2002)

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No. 09/724,575	Applicant(s)/Patent Under Reexamination SCHENK, DALE B.	
	Examiner Christopher Nichols, Ph.D.	Art Unit 1647	Page 4 of 5

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Frenkel et al. (1998) N-terminal EFRH Sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. Journal of Neuroimmunology 88: 85-90.
	V	Frenkel et al. (2000) Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. PNAS 97(21) 11455-11459.
	W	Frenkel et al. (1999) High Affinity Binding of Monoclonal Antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. Journal of Neuroimmunology 95: 136-142.
	X	Grubeck-Lobenstein et al. (2000) Immunization of beta-amyloid: could T-cell activation have a harmful effect? TINS 23: 114.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**Notice of References Cited**

Application/Control No.

09/724,575

Applicant(s)/Patent Under

Reexamination

SCHENK, DALE B.

Examiner

Christopher Nichols, Ph.D.

Art Unit

1647

Page 5 of 5

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Lemere et al. (2000) Nasal Abeta Treatment Induces anti-Abeta antibody production and decreases cerebral amyloid burden in PD-APP mice." Annals of the NY Acad. Sci. 920: 328-331.
	V	Chapman (2000) Model Behavior. Nature 408: 915-916.
	W	Small et al. (2001) Alzheimer's Disease and Abeta Toxicity: from top to bottom. Nat Rev Neurosci. 2(8): 595-8.
	X	Perutz et al. (2002) "Amyloid Fibers are Water-Filled Nanotubes" PNAS 99(8): 5591-5595.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.